Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma

Video details
YouTube Studio dashboard

Skip navigation
Search across your channel

Create

Videos
Video thumbnail: Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma
3:57
Your video
Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma
Details
Analytics
Editor
Comments
Languages
Earn
Copyright
Clips
Settings
Send feedback
Video details

Undo changes

Save
A/B Testing titles
Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma

View test report

Edit title
Description
In this HealthTree video, Dr. Adam Cohen discusses the Phase 2 STEM trial, which evaluates the safety and efficacy of cevostamab consolidation therapy following BCMA-directed CAR T-cell therapy in patients with heavily pretreated relapsed/refractory multiple myeloma.
Cevostamab, a bispecific antibody targeting FcRH5 and CD3, aims to enhance T-cell engagement against myeloma cells, potentially improving outcomes in this challenging patient population.

Presented at the 22nd International Myeloma Society Annual Meeting, the STEM trial's findings suggest that fixed-duration cevostamab consolidation is feasible and well-tolerated, with promising response rates.

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Products
Thumbnail
Set a thumbnail that stands out and draws viewers' attention. Learn more

Get suggestions
Playlists
Add your video to one or more playlists to organize your content for viewers. Learn more
IMS 2025 - International Myeloma Society Myeloma News Coverage
Audience
This video is set to not made for kids 
Set by you
Regardless of your location, you're legally required to comply with the Children's Online Privacy Protection Act (COPPA) and/or other laws. You're required to tell us whether your videos are made for kids. What's content made for kids?
Features like personalized ads and notifications won’t be available on videos made for kids. Videos that are set as made for kids by you are more likely to be recommended alongside other kids’ videos. Learn more
Yes, it's made for kids.Features like personalized ads and notifications won’t be available on videos made for kids. Videos that are set as made for kids by you are more likely to be recommended alongside other kids’ videos. Learn more
No, it's not made for kids

Age restriction (advanced)

Show more
Paid promotion, collaboration, and more
 

0:00 / 3:57
Video link
https://youtu.be/ndvHWi2H0BA
Filename
2025_09_19 Adam Cohen.mp4
Video quality
Notices
—
Visibility
Public
Subtitles
End screen
Cards
Quizzes
Files